Retrospective Analysis of Laryngeal Cancer Patients in a Tertiary Referral Center

• Published in: Turkish Archives of Otorhinolaryngology Vol. 62; no. 1; pp. 21 - 29
• Main Authors: Sungur, Ali Can, Bayır, Ömer, Toptaş, Gökhan, Aksoy, Şevket, Karahan, Sevilay, Yücel, Volkan, Çadallı Tatar, Emel, Saylam, Güleser, Korkmaz, Mehmet Hakan
• Format: Journal Article
• Language: English
• Published: Galenos Yayincilik 03.07.2024
• Subjects: clinical oncology; laryngeal cancer; laryngectomy; organ preservation; squamous cell carcinoma; survival
• ISSN: 0304-4793; 1303-6289; 2667-7474
• DOI: 10.4274/tao.2024.2023-12-2

Objective: In this study, we aimed to evaluate the effects of demographic data and comorbid diseases on the prognosis and treatment diagnosed with laryngeal squamous cell cancer (LSCC). Methods: Medical records of LSCC patients treated and followed up in a single referral center between 2008 and 2019 were retrospectively reviewed. In addition to the demographic data, the results of overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), locoregional-free survival (LRFS), and factors affecting recurrence were analyzed. Results: We included 573 patients with a mean age of 60.1±9.8 years. Of the 573 patients, 94.2% (540) were men, 93.7% (537) were smokers, 40.1% had at least one comorbid disease, and 69.8% (400) presented with glottic LSCC. The five-year OS, DSS, DFS, and LRFS rates for all cases were 65.7%, 79.9%, 67%, and 74.7%, respectively. In early-stage LSCC treatment, the rates of OS (p=0.008), DFS (p=0.024) and LRFS (p=0.01) were statistically significantly higher in the endolaryngeal laser surgery (ELS) group compared with the radiotherapy (RT) group. In advanced-stage LSCC treatment, total laryngectomy had statistically significantly higher five-year DFS (p=0.003) and LRFS (p=0.002) rates compared to chemoradiotherapy. Conclusion: Our study showed that ELS provided higher rates of OS, DFS, and LRFS compared to RT in the treatment of early-stage LSCC. Recurrence was significantly higher in supraglottic tumors, advanced-stage tumors, and in patients with clinical N positivity.